Abstract
Brucellosis, caused by Brucella species, remains a significant zoonotic disease affecting both human and animal health worldwide. Among the outer membrane proteins (Omps) of Brucella, Omp16 has emerged as a key immunogenic target with potential applications in vaccine development and diagnostics. Omp16, a lipidated peptidoglycan-associated lipoprotein, stimulates a strong proinflammatory response and is essential for maintaining the bacterial outer membrane integrity and facilitating host cell invasion. This review examines the immunogenic properties of Omp16, its role in Brucella pathogenesis, and its potential as a candidate for vaccine development. We discuss how Omp16-based vaccines, including recombinant proteins, outer membrane vesicles, and viral vector vaccines, have shown promise in providing protection against Brucella infections in animal models. Additionally, Omp16's utility in diagnostic applications, particularly in enzyme-linked immunosorbent assays (ELISA), offers a reliable method for detecting brucellosis in both humans and animals. Overall, Omp16 represents a crucial antigen with significant potential for advancing both the diagnosis and prevention of brucellosis, offering insights into the next generation of brucellosis vaccines and diagnostic tools.